← Leaderboards
Michael David Farwell
University Of Pennsylvania
$4,041,739
Attributed
$6,792,047
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,792,047 · 3
By mechanism
R01$3,885,865 · 2
UG3$2,906,182 · 1
Top collaborators
- Daniel J. Powell6 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Stephen G Emerson$28,932,839
- Carl H. June$35,377,952
- James L Riley$56,591,102
- Peter J O'Dwyer$138,294,037
- Meenhard Herlyn$50,214,821
Others in their field
Other Emerging Leaders on “Normal Tissue Morphology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$24,664,682
- Lynn Briscoe · Leidos Biomedical Research, Inc.$23,339,595
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Quy Phung · Leidos Biomedical Research, Inc.$12,889,396
- Leonard Freedmand · Leidos Biomedical Research, Inc.$9,965,931
Research focus
Normal Tissue MorphologyImage GuidedResponseCessation Of LifePet/Ct ScanCellsMediatingPositron-Emission TomographyToxic EffectTumorTheranosticsSmall MoleculeBiologicalDesignCellular TargetingDiagnostic ImagingAntitumor ResponseAntibodiesCouplingDockingAntigen TargetingCompanion DiagnosticsBiodistributionBinding
Grant awards (8)
Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatment$1,453,091
UG3 · FY2025 · CA
Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer$654,915
R01 · FY2025 · CA · contact PI
Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatment$1,453,091
UG3 · FY2024 · CA
Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer$636,515
R01 · FY2024 · CA · contact PI
Quantitative control of CAR T cells via image-guided delivery and monitoring$638,831
R01 · FY2021 · EB
Quantitative control of CAR T cells via image-guided delivery and monitoring$651,868
R01 · FY2020 · EB
Quantitative control of CAR T cells via image-guided delivery and monitoring$651,868
R01 · FY2019 · EB
Quantitative control of CAR T cells via image-guided delivery and monitoring$651,868
R01 · FY2018 · EB